Eisai Announces Canadian Launch of Halaven(TM) (eribulin mesylate) Injection For The Treatment of Metastatic Breast Cancer
New Treatment Option Significantly Prolongs Overall Survival in
Pre-treated Metastatic Breast Cancer Patients
MISSISSAUGA, ON, April 24, 2012 /PRNewswire/ – Eisai Limited, a wholly-owned
Canadian subsidiary of Eisai Inc., announced today the launch of
Halaven(TM) (eribulin mesylate), the latest treatment approved by Health
Canada for metastatic breast cancer. Halaven(TM) is indicated for the treatment of patients with metastatic breast cancer
who have previously received at least two chemotherapeutic regimens for
the treatment of metastatic disease. Prior therapy should have
included an anthracycline and taxane either in the adjuvant or
metastatic setting. Discovered and developed by Eisai, Halaven(TM) is a
non-taxane microtubule dynamics inhibitor that is a synthetic analogue
of halicondrin B, a product isolated from the marine sponge Halichondria okadai.
“Each year, approximately 23,000 Canadian women are diagnosed with
breast cancer and everyday 14 women will die from this aggressive
disease,” says Dr. Shailendra Verma, Medical Oncologist, The Ottawa
Hospital, Cancer Centre. “With the approval of Halaven(TM) in Canada, we
can offer a new single-agent therapy that is proven to significantly
improve survival in women with metastatic breast cancer.”
The approval of Halaven(TM) is based on the results from the pivotal Phase
III clinical study EMBRACE (Eisai Metastatic Breast Cancer Study
Assessing Physician’s Choice versus Eribulin) which showed that
patients treated with Halaven(TM) survived a median of 2.5 months longer
than patients who received a single agent therapy chosen by the
physician (Treatment of Physician’s Choice (TPC)). The overall
survival results were statistically significantly longer for Halaven(TM)
treated patients versus those receiving TPC. Overall survival was 13.12
months with Halaven versus 10.65 months with TPC (p=0.041). In an
updated survival analysis, conducted when 77 per cent of events had
been observed, the result was consistent with the primary analysis.
“Patients dealing with a cancer diagnosis struggle on a daily basis,”
says Cathy Ammendolea, Board Chair, Canadian Breast Cancer Network.
“Halaven represents a new option for patients with metastatic breast
cancer, proven to prolong survival.”
“Eisai is pleased to bring Halaven(TM) to Canada to help women in their
fight against metastatic breast cancer,” says Takihiro Hirasawa,
President, Eisai Limited “Halaven(TM) is the first women’s oncology
product for Eisai and links our corporate mission to fulfill unmet
medical needs. Eisai will continue to develop oncology treatments and
supportive therapies to improve the standard of care for patients
dealing with a cancer diagnosis in Canada.”
The most common side effects reported by patients receiving Halaven(TM)
were low white blood cells, low red blood cells, weakness/tiredness,
hair loss, and numbness, tingling or burning in the hands and feet,
nausea and constipation.
About Metastatic Breast Cancer
Metastatic breast cancer is an advanced stage of the disease that occurs
when cancer spreads beyond the breast to other parts of the body.
In Canada, over 23,000 women will be diagnosed with breast cancer. It
is the second most common cause of cancer death in women, resulting in
approximately 5,000 deaths per year.(1)
Although statistics on metastatic breast cancer may vary, on average, 64
Canadian women will be diagnosed with breast cancer every day(2) and a woman diagnosed with early stage breast cancer today has about an
85 per cent chance of being alive and disease free in 5 years.
About Halaven(TM) (eribulin mesylate) Injection
Halaven(TM) is the first agent in the halichondrin class of drugs.
Halaven(TM) is a non-taxane, microtubule dynamics inhibitor, derived from
the marine sponge Halichondria okadai. It is believed to work by inhibiting the growth phase of microtubule
dynamics without affecting the shortening phase and sequesters tubulin
into nonproductive aggregates.
Halaven(TM) (eribulin mesylate) is indicated for the treatment of patients
with metastatic breast cancer who have previously received at least two
chemotherapeutic regimens for the treatment of metastatic disease.
Prior therapy should have included an anthracycline and a taxane
administered in either the adjuvant or metastatic setting.
About the EMBRACE Clinical Trial
EMBRACE was an open-label, randomized, global, multi-center study
designed to compare overall survival in patients treated with Halaven(TM)
versus a Treatment of Physician’s Choice (TPC arm). TPC was defined as
any single-agent chemotherapy, hormonal treatment or biologic therapy
approved for the treatment of cancer; or palliative treatment or
radiotherapy administered according to local practice. The study
included 762 patients with metastatic breast cancer who previously had
been treated with an average of four prior chemotherapies. The vast
majority of patients in the TPC arm received chemotherapy.
About Eisai Limited
Eisai established Canadian pharmaceutical company Eisai Limited in 2010.
As a wholly-owned subsidiary of Eisai Inc., Eisai Limited is based in
Mississauga, Ontario, one of the largest biopharmaceutical clusters and
medical communities in North America. For more information about Eisai
in Canada, please visit www.eisai.ca
About Eisai Co., Ltd.
Eisai Co., Ltd. is one of the world’s leading R&D-based pharmaceutical
companies that has defined its corporate mission as “giving first
thought to patients and their families and to increasing the benefits
health care provides,” which we call human health care (hhc).
Eisai concentrates its R&D activities in three key areas:
-- Neuroscience: Alzheimer's disease, multiple sclerosis, neuropathic pain, epilepsy, depression, etc. -- Oncology: Anticancer therapies; tumour regression, tumour suppression, antibodies, etc. and Supportive cancer therapies; pain relief, nausea, etc. -- Vascular/Immunological Reaction: Acute coronary syndrome, atherothrombotic disease, sepsis, rheumatoid arthritis, psoriasis, Crohn's disease, etc.
With operations in Canada, the U.S., Asia, Europe and its domestic home
market of Japan, we employ more than 11,000 people worldwide.
About Eisai Inc.
Eisai Inc. was established in 1995 and is ranked among the top-20 U.S.
pharmaceutical companies (based on retail sales). The Company began
marketing its first product in the United States in 1997 and has
rapidly grown to become a fully integrated pharmaceutical business.
Eisai’s areas of commercial focus include neurology, gastrointestinal
disorders and oncology/critical care. The Company serves as the U.S.
pharmaceutical operating company of Eisai Co., Ltd., a research-based
human health care (hhc) company that discovers, develops and markets
products throughout the world.
Eisai Inc. has a global product creation organization that includes U.S.
– based R&D facilities in Massachusetts, New Jersey, North Carolina and
Pennsylvania as well as manufacturing facilities in Maryland and North
Carolina. The Company’s areas of R&D focus include neuroscience,
oncology, vascular, inflammatory and immunological reaction, and
Broadcast video to support this story is available to download at:
SOURCE Eisai Limited
Video with caption: “Video: New Treatment Option Halaven(TM), Significantly Prolongs Overall Survival in Pre-treated Metastatic Breast Cancer Patients”. Video available at: http://stream1.newswire.ca/cgi-bin/playback.cgi?file=20120424_C8397_VIDEO_EN_12650.mp4&posterurl=http://photos.newswire.ca/images/20120424_C8397_PHOTO_EN_12650.jpg&clientName=Eisai%20Limited&caption=Video%3A%20New%20Treatment%20Option%20Halaven%26%238482%3B%2C%20Significantly%20Prolongs%20Overall%20Survival%20in%20Pre%2Dtreated%20Metastatic%20Breast%20Cancer%20Patients&title=%20New%20Treatment%20Option%20Halaven%26%238482%3B%2C%20Significantly%20Prolongs%20Overall%20Survival%20in%20Pre%2Dtreated%20Metastatic%20Breast%20Cancer%20Patients&headline=Eisai%20Announces%20Canadian%20Launch%20of%20Halaven%26%23×2122%3B%20%28eribulin%20mesylate%29%20Injection%20For%20The%20Treatment%20of%20Metastatic%20Breast%20Cancer
Audio with caption: “Audio: ANR #1 – New Treatment Option Halaven(TM), Significantly Prolongs Overall Survival in Pre-treated Metastatic Breast Cancer Patients”. Audio available at: http://stream1.newswire.ca/media/2012/04/24/20120424_C8397_AUDIO_EN_12656.mp3
Audio with caption: “Audio: ANR #2 – New Treatment Option Halaven(TM), Significantly Prolongs Overall Survival in Pre-treated Metastatic Breast Cancer Patients”. Audio available at: http://stream1.newswire.ca/media/2012/04/24/20120424_C8397_AUDIO_EN_12657.mp3